FibroBiologics Inc FBLG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FBLG is a good fit for your portfolio.
News
-
FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment
-
FibroBiologics to Present at Advanced Wound Care Summit USA
-
FibroBiologics Appoints Ruben A. Garcia as General Counsel
-
FibroBiologics Files 2023 Form 10-K Annual Report
-
FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum
-
FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases
-
FibroBiologics Announces Three United States Patents for Fibroblast Technology
Trading Information
- Previous Close Price
- $9.22
- Day Range
- $8.74–9.01
- 52-Week Range
- $6.53–46.00
- Bid/Ask
- $8.84 / $9.04
- Market Cap
- $293.49 Mil
- Volume/Avg
- 2,482 / 90,628
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 8
- Website
- https://www.fibrobiologics.com
Valuation
|
Metric
|
FBLG
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 238.98 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FBLG
|
|---|---|
Quick Ratio | 1.00 |
Current Ratio | 1.00 |
Interest Coverage | −111.14 |
Quick Ratio
FBLG
Profitability
|
Metric
|
FBLG
|
|---|---|
Return on Assets (Normalized) | −133.81% |
Return on Equity (Normalized) | −306.00% |
Return on Invested Capital (Normalized) | −180.63% |
Return on Assets
FBLG
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bhjwsmxdc | Mfbnc | $567.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kbsfkkbh | Jzrclq | $106.9 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dvzscmzh | Yhhfyq | $105.9 Bil | |
MRNA
| Moderna Inc | Jqsvdlqp | Dnsb | $46.4 Bil | |
ARGX
| argenx SE ADR | Qlgqxkms | Yqv | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Vbcrvcb | Qksts | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mlkflmnh | Zhbqm | $19.5 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Myqdyzrd | Rlqspl | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yxygfgyps | Dmpyyf | $12.8 Bil | |
INCY
| Incyte Corp | Grqqwnsz | Qrrcxyj | $12.2 Bil |